BriLife (IIBR-100) Vaccine Description The Brilife (IIBR-100) vaccine candidate contains a recombinant vesicular stomatitis virus (VSV), an animal virus that does not cause disease in humans. The spike protein was replaced with that of SARS-CoV-2 that “results in rapid and potent induction of neutralizing antibodies against the SARS-CoV-2 coronavirus.”
Brilife (VSV ?G) is a vector-based vaccine that takes VSV and genetically engineers to express the spike protein of the SARS-CoV-2 beta coronavirus on its envelope. The human body recognizes the spike protein expressed on the envelope and begins to develop an immunological response.
In its collaboration with NRx, announced on July 12, 2021, the Israel Institute for Biological Research (IIBR) will provide technical assistance while receiving customary royalty and milestone payments for its intellectual property. NRx has further committed to supplying all required doses of the vaccine for the population of Israel. The initiative will be led by NRx Chairman and CEO Jonathan Javitt, together with NRx Director Chaim Hurvitz, who chairs CH Health, an Israeli Private Equity group.
BriLife (IIBR-100) Vaccine Cell Line BriLife (IIBR-100) Vaccine uses the following cell lines: Design and Development of BriLife (IIBR-100): BHK hamster cells, Vero monkey cells; Production: Vero Monkey Cells; Confirmatory Lab Tests: Plaque reduction; immunofluorescence, Vero monkey cells.
BriLife (IIBR-100) Vaccine History On June 19, 2020, a non-peer-reviewed study concluded the vaccine 'generated rVSV-?G-spike, a recombinant replication-competent VSV-based vaccine candidate expressing the SARS-CoV-2 spike protein. The rVSV-?G-spike resembles the SARS-CoV-2 in spike expression properties, antigenicity, and ability to induce neutralizing antibody production. Moreover, single-dose vaccination of hamsters with rVSV-?G-spike elicits a safe, effective, and sufficient neutralizing antibody response against the SARS-CoV-2 challenge.
The IIBR-100 vaccination protected SARS-CoV-2 inoculation, manifested in the rapid return to normal physiological parameters lung protection and rapid viral clearance. These results pave the way for further examination of rVSV-?Gspike in clinical trials as a vaccine against SARS-CoV-2.'
“Our final goal is 15 million doses for the residents of the State of Israel and our close neighbors,” said Prof. Shmuel Shapira, director of the Israel Institute for Biological research, reported to local media on October 26, 2020. Sheba Medical Center and Hadassah Medical Center stated they were chosen for a COVID-19 vaccine's initial trials. Both of these Israeli hospitals were selected because they have large facilities for clinical research.
On November 27, 2020, Jerusalem Post reported, “We are pleased to announce that the first phase of the clinical research trial of the coronavirus vaccine was a success,” said the director of the clinical research unit at Hadassah, Prof. Yossi Karko.
The Israel Institute for Biological research (IIBR) was established in 1952 as a governmental research institute founded by scientists from the IDF Science Corps and academic organizations under Isreal's Prime Minister's Office. IIBR is located in the city of Ness Ziona, Israel.
News 
Market Data 
Discover 
